{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-283230","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.658560+00:00","generated_at":"2026-05-16T19:54:29.687049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HCW Biologics Q3 net loss $4.6M; going concern doubt; first patient dosing expected Q4 2025","bullets":["Revenue fell to $15,606 from $426,423 YoY; net loss $4.6M vs $3.9M.","Substantial doubt about going concern for 12 months from Sep 30, 2025.","Nasdaq Panel granted continued listing subject to compliance with Equity Rule by Dec 31, 2025.","Issued 475,000 shares for $2.2M gross proceeds via Standby Equity Purchase Agreement.","Phase 1 trial of HCW9302 in autoimmune disease to dose first patient Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-283230","json":"https://secwatch.observer/filing/0001193125-25-283230.json","markdown":"https://secwatch.observer/filing/0001193125-25-283230.md","text":"https://secwatch.observer/filing/0001193125-25-283230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525283230/0001193125-25-283230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525283230/hcwb-20251114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:54:29.687049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}